160 related articles for article (PubMed ID: 15172086)
21. Atypical endometrial hyperplasia in an 18-year-old woman.
Agorastos T; Vaitsi V; Vakiani A; Dinas K; Bontis J
Arch Gynecol Obstet; 2003 Feb; 267(4):252-5. PubMed ID: 12592432
[TBL] [Abstract][Full Text] [Related]
22. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
23. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria.
Innala E; Bäckström T; Bixo M; Andersson C
Acta Obstet Gynecol Scand; 2010; 89(1):95-100. PubMed ID: 20021268
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis.
Kim NY; Ryoo U; Lee DY; Kim MJ; Yoon BK; Choi D
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):85-9. PubMed ID: 20832162
[TBL] [Abstract][Full Text] [Related]
26. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
27. Endometrial effects of tibolone in elderly, osteoporotic women.
Ettinger B; Kenemans P; Johnson SR; Mol-Arts M; Van Os S; Seifert W; Verweij PJ; Cummings SR
Obstet Gynecol; 2008 Sep; 112(3):653-9. PubMed ID: 18757665
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
[TBL] [Abstract][Full Text] [Related]
29. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
Weitzel JN; Buys SS; Sherman WH; Daniels A; Ursin G; Daniels JR; MacDonald DJ; Blazer KR; Pike MC; Spicer DV
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):654-8. PubMed ID: 17255289
[TBL] [Abstract][Full Text] [Related]
30. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
31. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.
Archer DF; Hendrix S; Ferenczy A; Felix J; Gallagher JC; Rymer J; Skouby SO; den Hollander W; Stathopoulos V; Helmond FA;
Fertil Steril; 2007 Oct; 88(4):866-78. PubMed ID: 17548089
[TBL] [Abstract][Full Text] [Related]
32. [THe use of leuprolide in endometrial glandular hyperplasia].
Menozzi G; Gozzi M; Greci P; Straticò G; Talarico G
Minerva Ginecol; 1992; 44(7-8):383-6. PubMed ID: 1407643
[TBL] [Abstract][Full Text] [Related]
33. [Endometriosis: clinical, histological and morphometric findings before and after Gn-RH agonist therapy].
Ruwe M; Donhuijsen K; Regidor PA; Leder LD; Schindler AE
Zentralbl Gynakol; 1998; 120(8):391-8. PubMed ID: 9757546
[TBL] [Abstract][Full Text] [Related]
34. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
Di Lieto A; De Falco M; Mansueto G; De Rosa G; Pollio F; Staibano S
Steroids; 2005 Feb; 70(2):95-102. PubMed ID: 15631865
[TBL] [Abstract][Full Text] [Related]
35. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
36. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
37. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
[TBL] [Abstract][Full Text] [Related]
39. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
40. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
